Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/130541
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, A. | - |
dc.contributor.author | Patterson, K.A. | - |
dc.contributor.author | Tan, D.J. | - |
dc.contributor.author | Wilson, M.E. | - |
dc.contributor.author | Proudman, S.M. | - |
dc.contributor.author | Stevens, W. | - |
dc.contributor.author | Nikpour, M. | - |
dc.contributor.author | Sahhar, J. | - |
dc.contributor.author | Ngian, G.-S. | - |
dc.contributor.author | Roddy, J. | - |
dc.contributor.author | Roberts-Thomson, P.J. | - |
dc.contributor.author | Walker, J.G. | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Scandinavian Journal of Rheumatology, 2021; 50(6):469-474 | - |
dc.identifier.issn | 0300-9742 | - |
dc.identifier.issn | 1502-7732 | - |
dc.identifier.uri | http://hdl.handle.net/2440/130541 | - |
dc.description | Published online: 14 Apr 2021 | - |
dc.description.abstract | Objective: We undertook a comprehensive cross-sectional analysis of a multicentred Australian cohort of systemic sclerosis (SSc) patients to evaluate the associations of anti-Ro52/TRIM21 with SSc pulmonary involvement. Method: The study included 596 patients from the Australian Scleroderma Cohort Study database whose anti-Ro52/TRIM21 status was known. Anti-Ro52/TRIM21 was measured via line immunoassay. Data on demographic variables, autoantibody profiles, presence of interstitial lung disease (ILD), presence of pulmonary arterial hypertension (PAH), oxygen saturation, Six-Minute Walk Test distance, Borg dyspnoea score, and lung function tests were extracted. SPSS software was used to examine associations using univariate and multivariate analyses. Results: Anti-Ro52/TRIM21 was present in 34.4% of SSc patients. In the cross-sectional analysis, anti-Ro52/TRIM21 was independently associated with PAH [odds ratio 1.75, 95% confidence interval (CI) 1.05–2.90], but not ILD or other surrogate measures of pulmonary involvement such as average patient oxygen saturation. The antibody, however, was also associated with a higher forced vital capacity/diffusing capacity of the lung for carbon monoxide ratio. Prospectively, anti-Ro52/TRIM21 was also associated with an increased risk of death in patients with SSc (hazard ratio 1.62, 95% CI 1.11–2.35), independent of confounding factors. The primary cause of death appeared to be related to PAH and/or ILD, and anti-Ro52/TRIM21 was associated with PAH-related complications. Conclusion: Anti-Ro52/TRIM21 was independently associated with PAH and mortality in SSc patients. Future longitudinal studies are recommended to investigate the timing and pathogenic mechanisms of this autoantibody in PAH. | - |
dc.description.statementofresponsibility | AYS Lee, KA Patterson, DJ Tan, ME Wilson, SM Proudman, W Stevens, M Nikpour, J Sahhar, G-S Ngian, J Roddy, PJ Roberts-Thomson, JG Walker | - |
dc.language.iso | en | - |
dc.publisher | Taylor & Francis | - |
dc.rights | © 2021 Scandinavian Journal of Rheumatology Foundation | - |
dc.source.uri | http://dx.doi.org/10.1080/03009742.2021.1887927 | - |
dc.subject | Humans | - |
dc.subject | Scleroderma, Systemic | - |
dc.subject | Autoantibodies | - |
dc.subject | Cohort Studies | - |
dc.subject | Cross-Sectional Studies | - |
dc.subject | Australia | - |
dc.subject | Pulmonary Arterial Hypertension | - |
dc.title | Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1080/03009742.2021.1887927 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/GNT1176538 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Proudman, S.M. [0000-0002-3046-9884] | - |
Appears in Collections: | Aurora harvest 4 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.